Barclays
MYGN icon

Barclays’s Myriad Genetics MYGN Stock Holding History

Barclays’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,500
Closed -$136K – 6022
2020
Q1 		$136K Sell
9,500
-10,400
-52% -$220K ﹤0.01% 4572
2019
Q4 		$542K Buy
19,900
+200
+1% +$5.5K ﹤0.01% 4232
2019
Q3 		$564K Sell
19,700
-54,100
-73% -$1.58M ﹤0.01% 4149
2019
Q2 		$2.05M Sell
73,800
-19,700
-21% -$556K ﹤0.01% 2881
2019
Q1 		$3.1M Buy
93,500
+91,300
+4,150% +$2.78M ﹤0.01% 2105
2018
Q4 		$64K Buy
2,200
+1,200
+120% +$43.2K ﹤0.01% 5340
2018
Q3 		$46K Hold
1,000
– – ﹤0.01% 6128
2018
Q2 		$37K Sell
1,000
-40,300
-98% -$1.36M ﹤0.01% 5829
2018
Q1 		$1.22M Buy
41,300
+39,900
+2,850% +$1.35M ﹤0.01% 2984
2017
Q4 		$48K Sell
1,400
-10,200
-88% -$344K ﹤0.01% 5785
2017
Q3 		$420K Buy
11,600
+11,300
+3,767% +$322K ﹤0.01% 3788
2017
Q2 		$8K Sell
300
-600
-67% -$12.7K ﹤0.01% 6117
2017
Q1 		$17K Sell
900
-13,400
-94% -$237K ﹤0.01% 5871
2016
Q4 		$238K Buy
14,300
+2,400
+20% +$43.4K ﹤0.01% 4075
2016
Q3 		$245K Buy
11,900
+7,600
+177% +$193K ﹤0.01% 3793
2016
Q2 		$132K Sell
4,300
-11,600
-73% -$403K ﹤0.01% 4212
2016
Q1 		$588K Buy
15,900
+5,400
+51% +$203K ﹤0.01% 3014
2015
Q4 		$452K Sell
10,500
-10,100
-49% -$427K ﹤0.01% 3295
2015
Q3 		$762K Sell
20,600
-30,700
-60% -$1.09M ﹤0.01% 2982
2015
Q2 		$1.69M Sell
51,300
-27,300
-35% -$928K ﹤0.01% 2373
2015
Q1 		$2.75M Buy
78,600
+26,600
+51% +$952K ﹤0.01% 2025
2014
Q4 		$1.77M Buy
52,000
+5,900
+13% +$209K ﹤0.01% 2639
2014
Q3 		$1.75M Sell
46,100
-12,600
-21% -$470K ﹤0.01% 2788
2014
Q2 		$2.23M Sell
58,700
-164,200
-74% -$6.11M ﹤0.01% 2478
2014
Q1 		$7.58M Sell
222,900
-261,100
-54% -$8.09M 0.01% 1371
2013
Q4 		$9.68M Buy
484,000
+224,100
+86% +$5.67M 0.01% 1276
2013
Q3 		$5.98M Sell
259,900
-203,900
-44% -$5.79M 0.01% 1540
2013
Q2 		$12.5M Buy
+463,800
New +$13.4M 0.02% 919

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's MYGN Position: Q1 2026 in Review

Barclays reduced its Myriad Genetics (MYGN) stake by 78% in Q1 2026, selling an estimated $1.22M and leaving 66,800 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #3472.

Barclays first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.9M in Q4 2019. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Barclays held 66,800 shares of Myriad Genetics worth $301K as of Q1 2026.
  • Barclays sold 234,988 Myriad Genetics shares in Q1 2026, an estimated $1.22M.
  • Myriad Genetics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3472 holding.
  • Barclays first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Myriad Genetics position peaked at $10.9M in Q4 2019.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.